Codex Labs launches Microbiome Modulating Products for Acne-Prone, Rosacea-Prone, and Eczema-Prone Skin

San Jose, Calif. - Jan 7th, 2026 - Codex Labs, a Silicon Valley skin-tech company, has launched two products to rebalance the skin microbiome and improve skin conditions: SHAANT Microbiome Balancing SKINDUO serum for acne-prone and rosacea-prone skin, and BIA Biome Reset Gel for eczema-prone skin. These innovative topicals help to shift the skin microbiome in favor of beneficial, commensal species to soothe irritation and reduce redness. They are optimized to work with Codex Labs cosmetic and OTC topicals that are non-microbiome modulating for a complete treatment strategy.

SHAANT Microbiome Balancing SKINDUO serums leverages live Lactobacillus plantarum to deliver broad anti-inflammatory and anti-pathogenic bacterial activity to help balance C. acnes and S. epidermidis populations within the skin microbiome. It also includes hyaluronic acid to improve skin hydration and lower oxidative stress. This innovative formulation is clinically proven to reduce the production of sebum, soothe the acne and rosacea inflammasomes, and minimize inflammatory lesions over time.

BIA Biome Reset Gel leverages phage lysates to deliver broad anti-S. aureus bacterial activity and niacinamide to helps soothe redness and irritation as well as strengthen the skin barrier to reduce water loss and the itch associated with dryness. This innovative and proprietary combination has also passed two MyMicrobiome Eczema certification standards: 27.11 Eczema Infant and 27.10 Eczema Adult.

"At Codex Labs, we are excited to introduce our novel microbiome-balancing topicals, which allow us to proactively address microbiome dysbiosis in skin conditions as well as provide skin barrier support." stated Dr. Barbara Paldus, CEO and Founder, Codex Labs. "They complement our non-microbiome modulating BIA and SHAANT portfolios of supplements, topicals and OTC treatments for those suffering from eczema, acne, or rosacea."

SHAANT Microbiome Balancing SKINDUO serum in vitro and clinical studies (*https://pubmed.ncbi.nlm.nih.gov/20456560/ [https://pubmed.ncbi.nlm.nih.gov/20456560/]) demonstrated:

*
43 to 57% decrease in sebum production (in vitro sebocyte model)

*
>90% decrease in IL-1a, IL-6 and IL-8 cytokine secretion (in vitro sebocyte model)

*
35% decrease in C. acnes population in 28 days (80 subjects, 2-3 grade acneic skin, Global Evaluation Acne Scale)

Both SHAANT Microbiome Balancing SKINDUO serum and BIA Biome Reset Gel are also MyMicrobiome-certified. They may be used together with Bia, Antu or Shaant topicals and supplements. This inside-out combination delivers skin comfort hydration, accelerated barrier repair, and minimizes flare-ups.

All Codex products are manufactured in high-tech GMP (Good Manufacturing Practice) facilities, to ensure they are made to the highest quality standards.

About Codex Labs

Based in Silicon Valley and led by Dr. Barbara Paldus, Codex Labs [http://www.codexlabscorp.com/] is pioneering a new era of clinically proven, microbiome-supporting, skin-gut-brain-biome solutions powered by potent, biotech-derived and plant-based actives. Trusted by integrative dermatologists and naturopathic doctors, our high-performance topicals and supplements are designed to restore and protect both skin and gut barriers. We are redefining care for compromised skin with our integrative telehealth platform, DECODE.ME [http://www.decode-me.com/], that connects consumers with expert practitioners to provide root cause diagnostics and personalized protocols that address both skin and gut health from the inside out.

Media Contact
Company Name: Otter Public Relations - Orlando Office
Contact Person: Anna Kate Womack
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=codex-labs-launches-microbiome-modulating-products-for-acneprone-rosaceaprone-and-eczemaprone-skin]
Address:150 E. Robinson Street
City: Orlando
State: Florida
Country: United States
Website: http://www.otterpr.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.